Concentric Medical announces treatment of first stroke patient with Merci Retriever

NewsGuard 100/100 Score

Concentric Medical, Inc., the global leader in devices for clot removal in acute ischemic stroke patients, today announced the treatment of the first patient in Japan with the Merci Retriever®.  The Merci Retriever is a catheter-based medical device that stroke centers use to remove blood clots from the brains of patients suffering an acute ischemic stroke.

Nobuyuki Sakai, M.D., D.M.Sc., Director, Neurosurgery & Stroke Center at Kobe City General Hospital said, "The Merci Retriever, which recently received Shonin approval in Japan, was used in its first case at Kobe City General Hospital.  We have been looking forward to the introduction of this device and we were very excited to have the first successful treatment of a cerebral artery occlusion in Japan.  I am confident that the neurosurgeons and neurologists at acute stroke centers will be using the Merci Retriever very shortly and enrolling patients in the post-market study.  The post-market study for the Merci Retriever will further validate the safety and efficacy in this new era of cerebral artery revascularization therapy."

Wade S. Smith, M.D., Ph.D., Professor of Neurology & Director, University of California, San Francisco Neurovascular Service and principal investigator of both the Merci and Multi Merci clinical trials said, "I am very happy to hear that the first patient in Japan has benefited from mechanical thrombectomy with the Merci Retriever.  It is my expectation that Japanese endovascular neurosurgeons and neurologists will rapidly change the status of stroke care in Japan using this stroke therapy, much like what has happened in the United States."

On May 4th, Concentric Medical announced the Shonin approval of the Merci Retriever®, Merci® Microcatheter, and Merci® Balloon Guide Catheter.  Century Medical Inc. of Japan is Concentric Medical's exclusive distribution partner. The two companies worked together to obtain Shonin approval for the Merci Retriever, which is the first device for clot removal for ischemic stroke patients to be approved in Japan.

Maria Sainz, President and CEO of Concentric Medical said, "I am thrilled that the first patient has been successfully treated with the Merci Retriever in Japan.  This first patient in Japan is a significant milestone for all those involved in making the Merci Retriever available to acute ischemic stroke patients throughout the world.  We look forward to working closely with Japanese physicians and our distribution partner, Century Medical, to drive the successful adoption of Merci. The approval and clinical use of the Merci Retriever in Japan is another example of how we continue to build on our strong heritage in the treatment of acute ischemic stroke."

Akira Hoshino, President and CEO of Century Medical said, "The initial patient treated with the Merci Retriever in Japan is very rewarding for everyone involved in the advancement of interventional stroke care in Japan.  This initial case is an exciting example of how the Merci Retriever provides a unique treatment option for physicians and stroke patients in Japan.  Century Medical is strongly committed to working with physicians and hospitals throughout Japan to make the Merci Retriever widely available for Japanese stroke patients."

Source:

Concentric Medical, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Global life expectancy rises by 6.2 years since 1990 despite COVID-19 setbacks